CN120392997A - 用于皮下注射的抗ifnar1给药方案 - Google Patents

用于皮下注射的抗ifnar1给药方案

Info

Publication number
CN120392997A
CN120392997A CN202411936092.4A CN202411936092A CN120392997A CN 120392997 A CN120392997 A CN 120392997A CN 202411936092 A CN202411936092 A CN 202411936092A CN 120392997 A CN120392997 A CN 120392997A
Authority
CN
China
Prior art keywords
dose
patients
ifngs
unit dose
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411936092.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·林德霍尔姆
Y·L·谢
R·图玛拉
L·罗斯科斯
J·阿尔姆奎斯特
T·劳斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81750490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN120392997(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority claimed from CN202280029635.7A external-priority patent/CN117157099A/zh
Publication of CN120392997A publication Critical patent/CN120392997A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Devices For Medical Bathing And Washing (AREA)
CN202411936092.4A 2021-04-23 2022-04-21 用于皮下注射的抗ifnar1给药方案 Pending CN120392997A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163178739P 2021-04-23 2021-04-23
US63/178,739 2021-04-23
US202163245285P 2021-09-17 2021-09-17
US63/245,285 2021-09-17
US202163272851P 2021-10-28 2021-10-28
US63/272,851 2021-10-28
CN202280029635.7A CN117157099A (zh) 2021-04-23 2022-04-21 用于皮下注射的抗ifnar1给药方案
PCT/EP2022/060592 WO2022223714A1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280029635.7A Division CN117157099A (zh) 2021-04-23 2022-04-21 用于皮下注射的抗ifnar1给药方案

Publications (1)

Publication Number Publication Date
CN120392997A true CN120392997A (zh) 2025-08-01

Family

ID=81750490

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411936092.4A Pending CN120392997A (zh) 2021-04-23 2022-04-21 用于皮下注射的抗ifnar1给药方案
CN202411940557.3A Pending CN120514844A (zh) 2021-04-23 2022-04-21 用于皮下注射的抗ifnar1给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411940557.3A Pending CN120514844A (zh) 2021-04-23 2022-04-21 用于皮下注射的抗ifnar1给药方案

Country Status (25)

Country Link
US (4) US20220340669A1 (https=)
EP (2) EP4114465B1 (https=)
JP (2) JP7484027B2 (https=)
KR (2) KR20250092298A (https=)
CN (2) CN120392997A (https=)
AU (2) AU2022260531B2 (https=)
BR (1) BR112023021761A2 (https=)
CA (1) CA3216387A1 (https=)
CL (1) CL2023003114A1 (https=)
CO (1) CO2023015498A2 (https=)
DK (1) DK4114465T5 (https=)
ES (1) ES2963757T3 (https=)
FI (1) FI4114465T3 (https=)
HR (1) HRP20231255T1 (https=)
HU (1) HUE063562T2 (https=)
IL (1) IL307748A (https=)
LT (1) LT4114465T (https=)
MX (1) MX2023012465A (https=)
PL (1) PL4114465T3 (https=)
PT (1) PT4114465T (https=)
RS (1) RS64821B1 (https=)
SI (1) SI4114465T1 (https=)
SM (1) SMT202300382T1 (https=)
TW (1) TW202317182A (https=)
WO (1) WO2022223714A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
WO2022106460A2 (en) * 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
CA3216395A1 (en) * 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN120392997A (zh) 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
AU2024277546A1 (en) 2023-05-19 2026-01-15 Astrazeneca Ab Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CN101678116A (zh) 2006-05-11 2010-03-24 根特大学 通过唾液酸粘附素靶向巨噬细胞
EP2712930A3 (en) 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
EP2666873B1 (en) 2007-07-12 2016-03-09 The Brigham and Women's Hospital, Inc. Compositions and methods for diagnosing and assessing inflammatory myopathies
NZ585064A (en) 2007-11-05 2012-08-31 Medimmune Llc Methods of treating scleroderma
KR20160070165A (ko) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
US20110287022A1 (en) 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
CA2772921A1 (en) 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
KR102320059B1 (ko) 2012-06-13 2021-11-01 아스트라제네카 아베 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
JP7013632B2 (ja) * 2018-09-18 2022-02-01 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 自己免疫疾患を治療するための抗ｉｆｎａｒ１抗体
SG11202108679PA (en) * 2019-02-15 2021-09-29 Astrazeneca Ab Type i interferon-mediated disorders
EP4494712A3 (en) 2019-11-11 2025-03-26 Astrazeneca AB Type i interferon inhibition in systemic lupus erythematosus
EP4157873A2 (en) 2020-05-29 2023-04-05 Astrazeneca AB Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
WO2022106460A2 (en) * 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
CA3216395A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN120392997A (zh) 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Also Published As

Publication number Publication date
US20230365698A1 (en) 2023-11-16
US20220340669A1 (en) 2022-10-27
CA3216387A1 (en) 2022-10-27
DK4114465T5 (da) 2024-07-22
TW202317182A (zh) 2023-05-01
EP4114465A1 (en) 2023-01-11
LT4114465T (lt) 2023-11-10
RS64821B1 (sr) 2023-12-29
IL307748A (en) 2023-12-01
KR20230166134A (ko) 2023-12-06
US12060429B2 (en) 2024-08-13
AU2022260531A1 (en) 2023-11-30
US20240360231A1 (en) 2024-10-31
DK4114465T3 (da) 2023-10-30
FI4114465T3 (fi) 2023-10-31
KR20250092298A (ko) 2025-06-23
JP7484027B2 (ja) 2024-05-15
BR112023021761A2 (pt) 2023-12-26
SMT202300382T1 (it) 2024-01-10
CO2023015498A2 (es) 2023-11-30
AU2024201743A1 (en) 2024-04-04
HUE063562T2 (hu) 2024-01-28
AU2022260531A9 (en) 2023-12-07
CN120514844A (zh) 2025-08-22
AU2022260531B2 (en) 2024-03-07
CL2023003114A1 (es) 2024-04-19
SI4114465T1 (sl) 2023-11-30
PT4114465T (pt) 2023-11-03
ES2963757T3 (es) 2024-04-01
JP2024511227A (ja) 2024-03-12
JP7805393B2 (ja) 2026-01-23
WO2022223714A1 (en) 2022-10-27
JP2024102205A (ja) 2024-07-30
EP4306541A2 (en) 2024-01-17
HRP20231255T1 (hr) 2024-02-02
PL4114465T3 (pl) 2024-04-08
EP4306541A3 (en) 2024-03-27
EP4114465B1 (en) 2023-08-30
US20240400699A1 (en) 2024-12-05
MX2023012465A (es) 2024-04-04

Similar Documents

Publication Publication Date Title
CN120392997A (zh) 用于皮下注射的抗ifnar1给药方案
US20250002589A1 (en) Treatment of cutaneous lupus erythematous
US20250002591A1 (en) Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients
CN118076379A (zh) 狼疮的治疗
KR20240038773A (ko) 루푸스의 치료
HK40087032B (en) Anti-ifnar1 dosing regime for subcutaneous injection
HK40087032A (en) Anti-ifnar1 dosing regime for subcutaneous injection
CN117157099A (zh) 用于皮下注射的抗ifnar1给药方案
EA052183B1 (ru) Лечение кожной красной волчанки
EA047082B1 (ru) Схема введения дозы антитела к ifnar 1 для подкожной инъекции
CN117337305A (zh) 系统性红斑狼疮患者中的1型干扰素受体抑制剂类固醇节制

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination